Featured Research

from universities, journals, and other organizations

Association between hormone replacement therapy use and breast cancer risk varies

Date:
September 3, 2013
Source:
Journal of the National Cancer Institute
Summary:
According to a new study, risk of breast cancer associated with use of hormone replacement therapy among postmenopausal women varies when analyzed by race/ethnicity, body mass index, and breast density.

Breast cancer risk associated with use of hormone replacement therapy (HRT) among postmenopausal women was variable when analyzed by race/ethnicity, body mass index (BMI), and breast density, according to a new study published September 3 in the Journal of the National Cancer Institute.

Studies have reported HRT use is associated with an increase in breast cancer risk. However, differential risks by BMI and breast density have been reported. Also, studies on the effect of HRT use on breast cancer risk among black women have reported inconsistent results.

Ningqi Hou, M.H.S., Ph.D., from the University of Chicago, in Chicago, IL, and colleagues analyzed 1,642,824 screening mammograms, which included 9,300 breast cancer cases, from postmenopausal women from the Breast Cancer Surveillance Consortium, a US registry of mammography screening. Data on HRT use were analyzed by race/ethnicity, age, BMI, and breast density using statistical methods to accommodate missing information on HRT use and other covariables. Statistically significant interactions between HRT use and each covariable were calculated.

A greater than 20% increased risk in breast cancer was associated with HRT use among white women and Hispanic women, but not black women. HRT use was more strongly associated with breast cancer risk in women with low or normal BMI but no association was observed among women with a high BMI. In addition, women with denser breasts had an increased likelihood of breast cancer among those who reported HRT use as well. The authors went on to investigate the combined effect of BMI and breast density because the two are correlated. They found a statistically significant interaction between breast density and HRT independent of BMI and identified high and low risk subgroups: HRT use was not associated with breast cancer for women with high BMI with low breast density whereas HRT use was associated with a statistically significant higher risk of breast cancer for women with low or normal BMI and high breast density.

These findings indicate HRT may be used for some women without increasing breast cancer risk, and could be used to help identify women who may use HRT to relieve postmenopausal symptoms without increasing their risk of breast cancer. Hou and colleagues conclude, "Black women, obese women, and women with breast tissue composed largely of fat may benefit from HRT use with minimal excess breast cancer risk." Further studies to confirm these findings and provide more information on other modifiable risk factors for breast cancer in relation to HRT use are needed.

In an accompanying editorial, Mary Beth Terry, Ph.D., and Parisa Tehranifar, Dr.P.H., from the Department of Epidemiology and the Herbert Irving Comprehensive Cancer Center at Columbia University, New York, NY, note that this study is the largest to investigate the association between HRT use and breast cancer risk by race/ethnicity, BMI, and breast density together. However, they also caution that the results were based on data for which details on HRT type and duration of use were not available and that the study was not adequately powered to investigate some interactions. cannot be used to draw They conclude, "Ultimately, efforts that improve risk stratification, whether made through improved risk models or through measuring valid intermediate biomarkers such as breast density, will inform appropriate use of not only HRT, but also other medications, including chemopreventive drugs."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. N. Hou, S. Hong, W. Wang, O. I. Olopade, J. J. Dignam, D. Huo. Hormone Replacement Therapy and Breast Cancer: Heterogeneous Risks by Race, Weight, and Breast Density. JNCI Journal of the National Cancer Institute, 2013; DOI: 10.1093/jnci/djt207

Cite This Page:

Journal of the National Cancer Institute. "Association between hormone replacement therapy use and breast cancer risk varies." ScienceDaily. ScienceDaily, 3 September 2013. <www.sciencedaily.com/releases/2013/09/130903193926.htm>.
Journal of the National Cancer Institute. (2013, September 3). Association between hormone replacement therapy use and breast cancer risk varies. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/09/130903193926.htm
Journal of the National Cancer Institute. "Association between hormone replacement therapy use and breast cancer risk varies." ScienceDaily. www.sciencedaily.com/releases/2013/09/130903193926.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins